WO1996017626A3 - Water soluble ubiquinone compositions, prodrugs, and methods relating thereto - Google Patents

Water soluble ubiquinone compositions, prodrugs, and methods relating thereto Download PDF

Info

Publication number
WO1996017626A3
WO1996017626A3 PCT/US1995/015888 US9515888W WO9617626A3 WO 1996017626 A3 WO1996017626 A3 WO 1996017626A3 US 9515888 W US9515888 W US 9515888W WO 9617626 A3 WO9617626 A3 WO 9617626A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
compositions
water soluble
methods relating
soluble ubiquinone
Prior art date
Application number
PCT/US1995/015888
Other languages
French (fr)
Other versions
WO1996017626A2 (en
Inventor
A Charles Morgan Jr
Scott S Graves
Clive S Woodhouse
Marianna Sikorska
Roy Walker
D Scott Wilbur
Henryk Borowy-Borowski
Original Assignee
Ryan Pharmaceuticals Inc
Univ Washington
Ca Nat Research Council
A Charles Morgan Jr
Scott S Graves
Clive S Woodhouse
Marianna Sikorska
Roy Walker
D Scott Wilbur
Borowy Borowski Henryk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryan Pharmaceuticals Inc, Univ Washington, Ca Nat Research Council, A Charles Morgan Jr, Scott S Graves, Clive S Woodhouse, Marianna Sikorska, Roy Walker, D Scott Wilbur, Borowy Borowski Henryk filed Critical Ryan Pharmaceuticals Inc
Priority to EP95943698A priority Critical patent/EP0796108A2/en
Priority to AU45105/96A priority patent/AU4510596A/en
Priority to JP8517760A priority patent/JPH10509732A/en
Publication of WO1996017626A2 publication Critical patent/WO1996017626A2/en
Publication of WO1996017626A3 publication Critical patent/WO1996017626A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

Water soluble ubiquinone compositions and prodrugs are disclosed (I). Methods of their delivery and use in the amelioration of apoptosis are also disclosed.
PCT/US1995/015888 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto WO1996017626A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95943698A EP0796108A2 (en) 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
AU45105/96A AU4510596A (en) 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
JP8517760A JPH10509732A (en) 1994-12-06 1995-12-06 Water-soluble ubiquinone compositions, prodrugs and related methods

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US35022094A 1994-12-06 1994-12-06
US08/350,220 1994-12-06
US48471895A 1995-06-07 1995-06-07
US48545095A 1995-06-07 1995-06-07
US48840095A 1995-06-07 1995-06-07
US48060695A 1995-06-07 1995-06-07
US48421395A 1995-06-07 1995-06-07
US48697395A 1995-06-07 1995-06-07
US08/486,973 1995-06-07
US08/485,450 1995-06-07
US08/480,606 1995-06-07
US08/484,718 1995-06-07
US08/488,400 1995-06-07
US08/484,213 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996017626A2 WO1996017626A2 (en) 1996-06-13
WO1996017626A3 true WO1996017626A3 (en) 1996-08-29

Family

ID=27569706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/015888 WO1996017626A2 (en) 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto

Country Status (5)

Country Link
EP (1) EP0796108A2 (en)
JP (1) JPH10509732A (en)
AU (1) AU4510596A (en)
CA (1) CA2207093A1 (en)
WO (1) WO1996017626A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889481B2 (en) * 1996-08-16 2007-03-07 株式会社カネカ Pharmaceutical composition
IT1290907B1 (en) * 1997-01-31 1998-12-14 Idi Farmaceutici Spa COMPOSITION BY DIET PRODUCT EFFECTIVE IN COMBATING OXIDATIVE STRESS AND CELL DECAY.
US6544797B1 (en) * 1997-04-09 2003-04-08 Biosite Diagnostics, Inc. Compositions and methods for inhibiting light-induced inactivation of biological reagents
DE19905880A1 (en) * 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE60030754T2 (en) * 1999-11-09 2007-09-20 Hybridon, Inc., Cambridge POTENTIATING THE EFFICACY OF SN-38 PRODROGEN
US6864231B2 (en) 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
TWI237018B (en) * 2001-07-13 2005-08-01 Kaneka Corp Method of producing reduced coenzyme Q10 crystals
CN100503543C (en) * 2001-07-13 2009-06-24 钟渊化学工业株式会社 Method of producing reduced coenzyme q10 as oily product
TWI310029B (en) * 2001-07-13 2009-05-21 Kaneka Corp
TW200604159A (en) * 2001-07-13 2006-02-01 Kaneka Corp Method of producing reduced coenzyme Q10 as oily product
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
ITRM20010755A1 (en) 2001-12-20 2003-06-20 Simonelli Giuseppe USE OF Q10 QUINONE FOR THE TREATMENT OF EYE DISEASES.
TWI349039B (en) * 2001-12-27 2011-09-21 Kaneka Corp Processes for producing coenzyme q10
JP4579835B2 (en) * 2003-01-10 2010-11-10 株式会社カネカ Purification method of reduced coenzyme Q10
WO2005000360A2 (en) 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CN1913925A (en) * 2003-12-10 2007-02-14 尼克塔治疗亚拉巴马公司 Compositions comprising two different populations of polymer-active agent conjugates
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US20070203080A1 (en) * 2006-02-15 2007-08-30 The Regents Of The University Of California New Drug Delivery System for Crossing the Blood Brain Barrier
JP5180556B2 (en) * 2006-10-13 2013-04-10 昭和電工株式会社 Skin external preparations and cosmetics containing ubiquinone derivatives or salts thereof, and methods of use thereof
US20080233056A1 (en) * 2007-03-19 2008-09-25 Zymes, Llc Organoleptic compounds with enhanced properties
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
WO2008134766A1 (en) * 2007-04-30 2008-11-06 Zymes, Llc Applications of ubiquinones and ubiquinols
AU2009233785B2 (en) 2008-04-11 2015-08-20 Berg Llc Methods and use of inducing apoptosis in cancer cells
KR20180056816A (en) 2009-05-11 2018-05-29 베르그 엘엘씨 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
CN102695413A (en) 2009-11-10 2012-09-26 麦赛尔控股有限公司 Stabilized formulations of fatty acids
AU2011224207B2 (en) 2010-03-12 2015-11-19 Berg Llc Intravenous formulations of Coenzyme Q10 (CoQ10) and methods of use thereof
US20120269867A1 (en) 2011-04-04 2012-10-25 Jimenez Joaquin J Methods of treating central nervous system tumors
PE20140628A1 (en) 2011-06-17 2014-05-30 Berg Llc INHALABLE PHARMACEUTICAL COMPOSITIONS
JP6310396B2 (en) * 2012-12-03 2018-04-11 株式会社カネカ Reduced coenzyme Q10 derivative and method for producing the same
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
MA47328A (en) 2017-10-24 2019-05-01 Difass Int S R L COMPOSITION CONSISTING OF COENZYME Q10 AND PIPERINE
CA3112583A1 (en) 2018-07-09 2020-01-16 New Age Nanotech Llc Stabilized formulations of cannabinoid compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2545511A1 (en) * 1974-10-11 1976-04-22 Eisai Co Ltd PROCESS FOR THE PREPARATION OF 1,4-BENZOHYDROCHINONE DERIVATIVES
DE2746398A1 (en) * 1976-10-19 1978-04-20 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING HYDROQUINONE AND QUINONE DERIVATIVES
JPS54160327A (en) * 1978-06-06 1979-12-19 Kuraray Co Ltd Preparation of coenzyme q
JPS5564538A (en) * 1978-11-06 1980-05-15 Ajinomoto Co Inc Preparation of dihydrocoenzyme q compound
EP0163317A1 (en) * 1984-05-31 1985-12-04 Eisai Co., Ltd. Quinone derivatives, method and use of preparing same, and pharmaceutical composition
EP0243849A2 (en) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Process for the production of polyprenoid type compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2545511A1 (en) * 1974-10-11 1976-04-22 Eisai Co Ltd PROCESS FOR THE PREPARATION OF 1,4-BENZOHYDROCHINONE DERIVATIVES
DE2746398A1 (en) * 1976-10-19 1978-04-20 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING HYDROQUINONE AND QUINONE DERIVATIVES
JPS54160327A (en) * 1978-06-06 1979-12-19 Kuraray Co Ltd Preparation of coenzyme q
JPS5564538A (en) * 1978-11-06 1980-05-15 Ajinomoto Co Inc Preparation of dihydrocoenzyme q compound
EP0163317A1 (en) * 1984-05-31 1985-12-04 Eisai Co., Ltd. Quinone derivatives, method and use of preparing same, and pharmaceutical composition
EP0243849A2 (en) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Process for the production of polyprenoid type compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORG. KHIM. (1978), 4(1), 109-16 CODEN: BIKHD7, 1978 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AJINOMOTO CO., INC., JAPAN: "Dihydrocoenzyme qs", XP002003386 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FUJITA, YOSHIJI ET AL: "Coenzyme Q", XP002003385 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KOZHUKHOVA, A. I. ET AL: "Synthesis of bifunctional inhibitors of mitochondrial NADH-dehydrogenase in a series of ubiquinol methyl ethers with modified isoprenoid side chains", XP002003384 *

Also Published As

Publication number Publication date
JPH10509732A (en) 1998-09-22
AU4510596A (en) 1996-06-26
CA2207093A1 (en) 1996-06-13
WO1996017626A2 (en) 1996-06-13
EP0796108A2 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
WO1996017626A3 (en) Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
ZA975212B (en) Compositions of modified carbon products and amphiphilic ions and methods of using the same.
ZA974871B (en) Concentrated liquid formulations.
AU4489997A (en) Thermal-fuse plug-through, plug-in diffuser
AU2125897A (en) Immunosuppressive compounds and methods
AU5371498A (en) Polymer film compositions for capsules
HK1018780A1 (en) 6-Phenylpyridine-2-ylamine derivatives, the composition and use thereof.
AU1262197A (en) Hydro-mechanical multi-string cutter
ZA991489B (en) Oxaliplatin solution formulations and the method of use thereof.
AU5130299A (en) Wrist-mounted i.v. administration set
ZA9711317B (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.
ZA975438B (en) Spray-dried polymer compositions and methods.
AU5493394A (en) Coating compositions, in particular for use in coating PVC sections
AU5686196A (en) Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
HUT75949A (en) 13-substituted milbemycin derivatives, their use as herbicids and herbicid compositions
EP0845495A3 (en) Cellulose particles, method for producing them and their use
AU3673395A (en) Gene participating in apoptosis
HK1021542A1 (en) Polymer compositions, their preparation and their use.
HK1007867A1 (en) Gel cleanser composition.
ZA9711489B (en) Craft copolymerized compositions.
EP1048641A4 (en) Apoptosis inducer
ZA978196B (en) Tricyclic indazole derivates, their preparation and their therapeutic application.
AU2842195A (en) Connector, in particular singel-entry connector
AU4777997A (en) Ion pairs, process for producing the same and their use as contrast agents
AU2747495A (en) Use of the enantiomers of oxazophosphorines, e.g. ifosfamide, in anti-tumour therapy, for reducing side-effects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2207093

Country of ref document: CA

Ref country code: CA

Ref document number: 2207093

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970703797

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995943698

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995943698

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970703797

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995943698

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970703797

Country of ref document: KR